Skip to main content

Pombiliti Disease Interactions

There is 1 disease interaction with Pombiliti (cipaglucosidase alfa).

Major

Hydrolytic lysosomal glycogen-specific enzymes (applies to Pombiliti) cardiac/pulmonary impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Fluid Retention, Heart Disease

Patients with an acute underlying illness at the time of avalglucosidase alfa or cipaglucosidase alfa infusion may be at greater risk for infusion-associated reactions (IARs); compromised cardiac and respiratory function may predispose patients to a higher risk of severe complications from IARs. Antihistamines, antipyretics, and/or corticosteroids can be given before avalglucosidase alfa or cipaglucosidase alfa infusion to reduce the risk of IARs; however, IARs may still occur in pretreated patients.

Patients susceptible to fluid volume overload, or patients with acute underlying respiratory illness or compromised cardiac or respiratory function for whom fluid restriction is indicated may be at risk of serious exacerbation of their cardiac or respiratory status during avalglucosidase alfa or cipaglucosidase alfa infusion; more frequent monitoring of vitals should be performed during infusion in such patients. Some patients may require prolonged observation times.

References

  1. (2021) "Product Information. Nexviazyme (avalglucosidase alfa)." Genzyme Corporation
  2. (2023) "Product Information. Pombiliti (cipaglucosidase alfa)." Amicus Therapeutics U.S., Inc.

Pombiliti drug interactions

There are 2 drug interactions with Pombiliti (cipaglucosidase alfa).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer